Glycoprotein vi antibodies and methods for producing and using such antibodies

FIELD: medicine.

SUBSTANCE: there are offered versions of a monoclonal antibody specific to GPVI polypeptide, peptide or its naturally occurred version. A based antithrombotic composition and a method for preparing thereof are described. The versions of methods for inhibition and treatment of various thrombocyte aggregation mediated diseases are disclosed. An antithrombotic set and hybridoma for producing the monoclonal antibody are described.

EFFECT: use of the invention provides the antibodies inhibiting thrombocyte aggregation that can find the further application in medicine for treating various thromboses.

13 cl, 16 dwg, 9 tbl, 10 ex

 

The text descriptions are given in facsimile form.

1. A monoclonal antibody specific to the GPVI polypeptide, peptide or a naturally occurring variant selected from OM, OM, OM and OM4, characterized in that the above-mentioned OM includes three hypervariable segment (CDRs) (sequence No. 1-3) on the first chain antibodies and three CRs (sequence No. 4-6) on the second chain antibodies; but such A includes three CDRs (sequence No. 7-9) on the first chain antibodies and three CDRs (sequence No. 10-12) on the second chain antibodies, but such A includes three CDRs (sequence No. 13-15) on the first chain antibodies and three CDRs (sequence No. 16-18) on the second chain antibodies, but such OM4 includes three CDRs (sequence No. 19-21) on the first chain antibodies and three CDRs (sequence No. 22-24) on the second chain antibodies;

2. Monoclonal humanitariannet OHM antibody specific to the GPVI polypeptide, peptide or a naturally occurring variant selected from gumanitarnogo AM, gumanitarnogo AM, gumanitarnogo AM and gumanitarnogo OM4, characterized in that the above-mentioned humanitariannet OM includes three hypervariable segment (CDRs) (sequence No. 1-3) on the first chain antibodies and three CDRs (sequence No. 4-6) on the second chain antibodies, but such humanitariannet OM includes three CDRs (sequence No. 7-9) on the first chain antibodies and three CDRs (sequence No. 10-12) on the second chain antibodies, but such humanitariannet OM includes three CDRs (sequence No. 13-15) on the first chain antibodies and three CDRs (sequence No. 16-18) on the second chain antibodies, but such humanitariannet OM4 includes three CDRs (sequence No. 19-21) is a first chain antibodies and three CDRs (sequence No. 22-24) on the second chain antibodies.

3. Antithrombine a composition comprising a therapeutically effective amount of at least one monoclonal antibody according to claim 1.

4. The method of preparation antithrombotic composition, comprising mixing at least one monoclonal antibody according to claim 1, in a pharmaceutically acceptable excipient.

5. A method of treating a patient suffering from vascular disease, including the appointment of a composition according to claim 3 to a patient.

6. A method of treating vascular disease in a patient, including the appointment of a composition according to claim 3 to a patient, wherein said treatment inhibits thrombosis.

7. Method of inhibiting platelet aggregation, including the introduction of platelets in contact with a composition according to claim 3, characterized in that the composition inhibits platelet aggregation.

8. The method of inhibition induced by collagen seretei ATP, including the introduction of platelets in contact with a composition according to claim 3, characterized in that the composition inhibits the secretion of ATP.

9. Method of inhibiting collagen-induced formation of thromboxane A2including the introduction of platelets in contact with a composition according to claim 3, characterized in that the composition inhibits collagen-induced formation of thromboxane A2.

10. Method of inhibiting adhesion of platelets, including joining the tion of platelets in contact with a composition according to claim 3, characterized in that the composition inhibits the adhesion of platelets.

11. Antithrombotic set containing at least one dose of a pharmaceutically effective amount of at least one monoclonal antibody according to claim 1, and pharmaceutically acceptable solvent or other filler in the container.

12. Monoclonal antibody according to claim 1, characterized in that said antibody is produced by hybridoma selected from the group consisting of a hybrid with the inventory numbers of ATCS no MOUTH-5938, MOUTH-5939, MOUTH-5940 and MOUTH-5941.

13. Hybridoma for producing monoclonal antibodies specific to the GPVI polypeptide, peptide or a naturally occurring variant selected from the group consisting of a hybrid with the inventory numbers of ATCS no MOUTH-5938, MOUTH-5939, MOUTH-5940 and MOUTH-5941.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to immunology and biotechnology. Claimed are versions of antibodies or their functional fragments, which are bound with receptor of human insulin-like growth factor I IGF-IR, and/or natural binding of its ligands IGF1 and/or IGF2 and/or are capable of specific inhibition of tyrosine kinase activity of said IGF-IR. Antibodies contain respective CDR sections of light and heavy chains. Described is mouse hybridoma I-3193 for production of antibodies. Composition for prevention or treatment of cancer, based on antibody application. Described is application of antibodies and/or composition for obtaining respective medication. Claimed is method of diagnostics in vitro of diseases, caused by over-expression or insufficient expression of receptor IGF-I based on antibodies..

EFFECT: invention application ensures antibodies able to bind with isophorms A and B insulin, insulin/ IGF-1 of hybrid receptors which can be applied in medicine for tumour treatment.

15 cl, 8 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: there are offered specific antibodies linked at least with KIR2DL1, KIR2DL2, KIR2DL3 human receptor, neutralise KIR-mediated NK cytolergy inhibition in relation to Cw3+ or Cw4+ target-cells. There are described: B-lymphocyte hybrid cell for producing the antibodies, versions of the method for producing the antibody, as well as a method for detecting a NK-cell, a method for purifying the NK-cells with the use of the antibody and versions of the pharmaceutical antibody composition. Using the antibody for preparing a medicinal agent is offered.

EFFECT: use of the invention provides producing the antibody which controls NK cytolergy of various types, intensifies cytotoxicity, increases NK cytolergy or cytotoxicity in individuals.

63 cl, 13 dwg, 3 tbl, 8 ex

FIELD: medicine; pharmacology.

SUBSTANCE: allocated human monoclonal antibodies which specifically bind a receptor of the epidermal growth factor (EGFR), and also corresponding compositions on the basis of antibodies and a biospecific molecule are described. Human antibodies can be received with use of the transgenic mouse capable to formation of set of isotypes of human monoclonal antibodies by recombination V-D-J and switching of isotypes. The pharmaceutical compositions containing human antibodies for treatment or prevention of diseases, mediated by expression EGFR, the transgenic animals distinct from a human, the specified expressing antibodies, hybridomes and transfectomes which produce human antibodies are also presented. Ways of therapy and diagnostics of the diseases mediated by expression EGFR, with use of human antibodies or their antigen-binding of fragments, and also methods of growth suppression of the cells expressing EGFR, and an induction of cytolysis of the specified cells are described.

EFFECT: invention allows obtaining therapeutic and diagnostic preparations of antibodies with improved properties.

53 cl, 22 dwg, 4 tbl, 11 ex

FIELD: biotechnology, immunology, medicine, oncology.

SUBSTANCE: strain of hybrid cultured mammalian cells Mus musculus VKPM H-98 is prepared by the hybridoma technology method. This strain is a producer of monoclonal antibodies possessing individual specificity to hypoglycosidated and deglycosidated isoforms of tumor-associated human antigen Muc I. Productivity of the strain and specificity of produced antibodies is estimated based on the immunoenzyme assay using some markers of specificity: natural purified antigen Muc I isolated from human milk; VNTR22-polypeptide; synthetic monomeric polypeptide (TR1); deglycosidated antigen Muc I (de-Muc I) prepared by chemical oxidation of natural Muc I; hypoglycosidated antigen Muc I (o-Muc I) prepared by periodate oxidation of natural Muc I. Monoclonal antibodies produced by the claimed strain recognize clinically significant isoforms of antigen Muc I and allows assaying its concentrations in human serum blood in carrying out the early diagnosis of tumors. Invention can be used in preparing monoclonal antibodies to tumor-associated human antigen Muc I.

EFFECT: valuable properties of strain.

2 dwg, 3 ex

FIELD: biotechnology, immunology, medicine, oncology.

SUBSTANCE: strain of hybrid cultured mammalian cells Mus musculus VKPM H-97 is prepared by the hybridoma technology method. This strain represents a producer of monoclonal antibodies possessing specificity to conformation-dependent of tumor-associated human antigen Muc I. Productivity of the strain and specificity of produced antibodies is estimated based on immunoenzyme assay using some markers of specificity: natural purified antigen Muc I isolated from human milk; VNTR22-polypeptide; synthetic monomeric polypeptide (TR1); deglycosidated antigen Muc I (de-Muc I) prepared by chemical oxidation of natural Muc I; hypoglycosidated antigen Muc I (o-Muc I) prepared by periodate oxidation of natural Muc I. Monoclonal antibodies produced by the claimed strain recognize clinically significant isoforms of Muc I antigen and allows assaying its concentration in human serum blood in carrying out early diagnosis. Invention can be used for preparing monoclonal antibodies to tumor-associated human antigen Muc I.

EFFECT: valuable properties of strain.

2 dwg, 3 ex

FIELD: medicine, biotechnology.

SUBSTANCE: invention proposes variants of antibodies showing specificity to peptide domain located by both side of hinged site R76S77 in pro-BNP(1-108). Indicated antibodies recognize specifically also circulating pro-BNP(1-108) in human serum or plasma samples but they don't recognize practically peptides BNP(1-76) or BNP(77-108). Also, invention describes variants of peptides used in preparing antibodies. Amino acid sequence is given in the invention description. Also, invention discloses methods for preparing indicated antibodies and among of them by using indicated peptides. Also, invention describes methods for preparing antibody-secreting hybridoma, and hybridoma is disclosed prepared by indicated method. Also, invention describes a monoclonal antibody secreted by hybridoma 3D4 and deposited at number CNCM I-3073. Also, invention discloses variants for diagnosis of cardiac insufficiency in vitro and by using antibodies proposed by the invention. Also, invention describes a set used for detecting pro-BNP(1-108) in a biological sample. Using this invention simplifies detection of pro-BNP(1-108) circulating in human serum or plasma samples and provides specific detection of pro-BNP(1-108) that can be used in early diagnosis of human cardiac insufficiency.

EFFECT: valuable medicinal properties of antibodies.

24 cl, 16 dwg, 5 tbl, 20 ex

FIELD: immunology.

SUBSTANCE: invention relates to immunoenzyme analysis and can be used for assay of von Willebrand factor. Method involves immunoenzyme analysis wherein monoclonal antibody 5C3 is used as an immobilizing antibody, and a mixture of biotin-labeled monoclonal antibodies 2H2 and 7D12 is used as a detecting antibody. Also, invention relates to monoclonal antibodies produced by the strain of hybridoma cultured cells Mus musculus L. and directed against von Willebrand factor, and to strains of hybrid cultured cells Mus musculus L. producing indicated monoclonal antibodies. Invention provides the development of highly sensitive method for assay of von Willebrand factor.

EFFECT: improved method for analysis.

9 cl, 1 tbl, 2 dwg, 3 ex

The invention relates to biotechnology, in particular to recombinant IL4-antibodies used for treating disorders associated with the activity IL4

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, and represents humanised anti-CD40-antibodies and their antigen-binding fragments, and also polynucleotides coding variable regions of the antibodies under the invention. Also, the pharmaceutical composition and a set on the basis of the specified antibodies are presented.

EFFECT: antibodies under the invention can be used effectively for treating a disease characterised by CD40 antigen expression.

25 cl, 5 dwg, 5 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to immunology, and concerns P-selectin glycoprotein ligand 1 modulators. Substance of the invention involves a multimeric compound which is bound with at least two (PSGL-1) proteins on a T-cell surface; said multimeric compound contains two polypeptide chains each of which contains a binding domain which is bound with PSGL-1 and which contains a P-selectin extracellular domain or its binding fragment, or E-selectin extracellular domain or its binding fragment, and also a heterologous amino acid sequence; two polypeptide chains are combined by the heterologous amino acid sequence to produce the multimeric compound.

EFFECT: advantage of the invention consists in the development of the agent to be used to induce T-cell depletion and/or apoptosis.

30 cl, 14 ex, 12 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes four humanized monoclonal anti-CD20-antibodies, obtained by cultivation of cells deposited under NoNo FERM BP-10543, BP-10544, BP-10545 and BP-10546. Each antibody by invention contains combination of L-chain and H-chain with amino acid sequence, represented in description. For each of presented in invention antibodies given are their specific characteristics, in particular constant of dissociation with respect to human CD20 antigen. Each of antibodies described above (one or in combination with other antibodies by invention) is intended as active ingredient in composition of therapeutic agent for treatment of diseases, mediated by B-cells. Invention also describes method of obtaining humanised monoclonal antibody with said characteristics with application of cells-producers, listed above.

EFFECT: invention ensures obtaining humanised monoclonal anti-CD20-antibodies for application as efficient therapeutic agents.

12 cl, 46 dwg, 7 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to immunology and biotechnology. Claimed are versions of antibodies or their functional fragments, which are bound with receptor of human insulin-like growth factor I IGF-IR, and/or natural binding of its ligands IGF1 and/or IGF2 and/or are capable of specific inhibition of tyrosine kinase activity of said IGF-IR. Antibodies contain respective CDR sections of light and heavy chains. Described is mouse hybridoma I-3193 for production of antibodies. Composition for prevention or treatment of cancer, based on antibody application. Described is application of antibodies and/or composition for obtaining respective medication. Claimed is method of diagnostics in vitro of diseases, caused by over-expression or insufficient expression of receptor IGF-I based on antibodies..

EFFECT: invention application ensures antibodies able to bind with isophorms A and B insulin, insulin/ IGF-1 of hybrid receptors which can be applied in medicine for tumour treatment.

15 cl, 8 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: binding molecule represents a CD45RO and CD45RB chimeric antibody. The molecule contains two domains with consistent hypervariable sites CDR1, CDR2 and CDR3, and CDR1', CDR2' and CDR3', CDR1 has amino acid sequence NYIIH, CDR2 has amino acid sequence YFNPYNHGTKYNEKFKG, and CDR3 has amino acid sequence SGPYAWFDT. CDR1' has amino acid sequence RASQNIGTSIQ, CDR2' has amino acid sequence SSSESIS, and CDR3' has amino acid sequence QQSNTWPFT. Related coding polynucleotide is described.

EFFECT: use of the invention allows to induce immunosuppression, to inhibit T-cell response and primary lymphocyte reaction in the mixed culture, to prolong survival time in mice with severe combined immunodeficiency SCID.

6 cl, 5 dwg, 2 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: there are offered specific antibodies linked at least with KIR2DL1, KIR2DL2, KIR2DL3 human receptor, neutralise KIR-mediated NK cytolergy inhibition in relation to Cw3+ or Cw4+ target-cells. There are described: B-lymphocyte hybrid cell for producing the antibodies, versions of the method for producing the antibody, as well as a method for detecting a NK-cell, a method for purifying the NK-cells with the use of the antibody and versions of the pharmaceutical antibody composition. Using the antibody for preparing a medicinal agent is offered.

EFFECT: use of the invention provides producing the antibody which controls NK cytolergy of various types, intensifies cytotoxicity, increases NK cytolergy or cytotoxicity in individuals.

63 cl, 13 dwg, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: there is described a recovered anti-FcγRIIB/anti-FcεRIα bispecific antibody unable of cross-linking with human FcγRIIA. There are offered methods of immune response inhibition in a mammal, immune response related histamine release inhibition in a mammal, and treatment involving the introduction of described bispecific antibody. There are presented a composition for FcεRI activity inhibition in the recovered cells of mammals, a composition for FcγRIIB activation in the recovered cells of mammals expressing FcγRIIB by combined aggregation of FcγRIIB and FcεRIα and a composition for FcεRI receptor expression inhibition in the recovered cells containing the described antibody as an active material.

EFFECT: invention allows making bispecific anti-FcγRIIB, anti-FcεRIα antibodies.

49 cl, 65 dwg, 2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology. The pharmaceutical composition for destruction of tumor cells expressing the receptor CCR7 is described, which contains an antibody binding to the receptor CCR7, and a pharmaceutically acceptable carrier. Versions of methods of eradication of tumor cells expressing the receptor CCR7 are proposed, which include either contacting of the specified cells with an antibody that binds with the specified receptor CCR7, or administering to the patient a therapeutically effective amount of an antibody that binds with the specified receptor CCR7.

EFFECT: invention expands the amount of means for cancer treatment.

6 cl, 8 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to method of treating tumour by introduction to subject of c-met antagonist, where lung tumour contains hyperstabilised polypeptide of human c-met with deletion of amino acid part L964 - D1010 of amino acid sequence (given in formula), due to which c-met degradation is reduced in comparison with c-met if wild type. Hyperstabilised polypeptide of c-met binds c-met ligand and possesses c-met activity with respect to signal transmission. In invention it is shown that antagonist is introduced together with substance, inducing degradation of receptor protein. C-met antagonist can represent peptide-antagonist, antibody-c-met antagonist, in particular monovalent antibody, humanised, human or chimeric.

EFFECT: invention makes it possible to inhibit c-met activity with antagonist due to enhancement of cell degradation of hyperstabilised c-met protein either due to inhibition of phosphorolation of hyperstabilised c-met protein or member of cascade of HGF-c-met signal transmission.

10 cl, 1 ex, 18 dwg

FIELD: medicine.

SUBSTANCE: there is claimed isolated human antibody or its fragment, which binds to human EGFR. Antibody contains corresponding CDR areas of light and heavy chain. Its conjugate with anti-neoplastic means or marker is described. Also described are: coding nucleic acid, expression vector, recombinant cell-host for obtaining antibodies and method of inhibiting growth of tumor, expressing EGFR on the basis of antibody.

EFFECT: application of invention provides antibodies with affinity comparable or higher, than in IMC-C225, which neutralises EGFR activation, what can be applied in medicine for treatment of tumours.

36 cl, 14 dwg, 6 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 3-cyclohexylaminomethylthiazole[3,2-a]benzimidazole dihydrochloride of formula I: , having immunotropic and anti-aggregation activity.

EFFECT: novel compounds have useful biological properties.

2 cl, 8 tbl, 3 ex

Up!